Trial reportAnnals of medicine2025
Anterior quadratus lumborum block at the lateral supra-arcuate ligament versus thoracic paravertebral block for postoperative analgesia after laparoscopic nephrectomy: a randomized non-inferiority trial.
Trial report in Annals of medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis study compared the analgesic effects of the anterior quadratus lumborum block at the lateral supra-arcuate ligament (QLB-LSAL) and thoracic paravertebral block (TPVB) for laparoscopic nephrectomy to verify whether the new quadratus lumborum block is an efficient technique for managing laparoscopic nephrectomy pain as an alternative to TPVB.
methodsThis study was a prospective randomized noninferiority clinical trial. Before general anaesthesia, 80 participating patients were randomly allocated to receive QLB-LSAL (20 mL of 0.5% ropivacaine) or TPVB (20 mL of 0.5% ropivacaine). The primary outcome was the mean visual analogue scale (VAS) score in the first 24-hafter surgery. The secondary outcomes included the cutaneous sensory block area, intraoperative haemodynamic changes, consumption of sufentanil at 24-h postoperatively, and postoperative recovery data.
resultsThe mean VAS score during the first 24-h was 1.92 ± 0.28 in the QLB-LSAL group and 1.79 ± 0.25 in the TPVB group. The mean treatment difference (QLB-LSAL-TPVB) in the primary outcome was 0.13 (95% CI 0.02 to 0.25). The upper limit of the 95% CI remained below the non-inferiority margin. After 10 and 30 min, the TPVB group had significantly greater cutaneous sensory block area (
conclusionsAt 24-h postoperatively, QLB-LSAL had analgesic effects that were not inferior to those of TPVB for patients undergoing laparoscopic nephrectomy.
trial registrationChinese Clinical Trial Registry website; registration number: ChiCTR2100048226.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.